ObsEva Company

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, Ph.D. and André Chollet Ph.D. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company that was acquired by Gedeon Richter in 2010. André Chollet is a specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.
Technology: Longevity FemTech
Industry: FemTech
Headquarters: Geneve, Switzerland
Founded Date: 7-4
Employees Number: 11-50
Funding Status: IPO
Investors Number: 17
Total Funding: $228.4M
Estimated Revenue: Less than $1M
Last Funding Type: Post-IPO Debt

Visit Website
Register and Claim Ownership